Open AccessVortioxetine reverses medial prefrontal cortex-mediated cognitive deficits in male rats induced by castration as a model of androgen deprivation therapy for prostate cancer
Author(s) -
Alexandra M. Sharp,
Suphada Lertphinyowong,
Samantha S. Yee,
Denisse Paredes,
Jonathan Gelfond,
Teresa L. JohnsonPais,
Robin J. Leach,
Michael A. Liss,
April L. Risinger,
Anna Campbell Sullivan,
Ian M. Thompson,
David A. Morilak
Publication year - 2019
Publication title -
psychopharmacology/psychopharmacologia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.378
H-Index - 196
eISSN - 1432-2072
pISSN - 0033-3158
DOI - 10.1007/s00213-019-05274-4
Subject(s) - vortioxetine , prostate cancer , androgen deprivation therapy , enzalutamide , psychology , prefrontal cortex , neuroscience , medicine , antidepressant , androgen , hippocampus , oncology , cognition , androgen receptor , cancer , hormone
Androgen deprivation therapy (ADT) is an effective treatment for prostate cancer, but induces profound cognitive impairment. Little research has addressed mechanisms underlying these deficits or potential treatments. This is an unmet need to improve quality of life for prostate cancer survivors.